Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases

Abstract

We conducted a single-centre retrospective cohort study in a French University Hospital between 2010 and 2018 to describe the risk of severe infectious event (SIE) within 2 years after the date of first rituximab infusion (T0) prescribed after the evidence of acquired hypogammaglobulinemia (gamma globulins [GG] ≤ 6 g/L) in the setting of autoimmune diseases (AID) other than rheumatoid arthritis. SIE occurred in 26 out of 121 included patients. Two years cumulative incidence rates were 12.7 % (95 % CI 5.1–23.9) in the multiple sclerosis/neuromyelitis optica spectrum disorder group (n = 48), 27.6 % (95 % CI 15.7–40.9) in the ANCA-associated vasculitis group (n = 48) and 30.6 % (95 % CI 13.1–50.3) in the ‘other AID’ group (n = 25). Median GG level at T0 was 5.3 g/l (IQR 4.1–5.6) in the 'SIE' group and 5.6 g/l (IQR 4.7–5.8) in the 'no SIE' group (p = 0.04).In regression analysis, risk of SIE increased with Charlson comorbidity index ≥ 3 (OR 2.77; 95 % CI 1.01–7.57), lung disease (OR 3.20; 95 % CI 1.27–7.99), GG < 4 g/L (OR 3.39; 95 % CI 1.02–11.19), concomitant corticosteroid therapy (OR 4.13; 95 % CI 1.63–10.44), previous cyclophosphamide exposure (OR 2.69; 95 % CI 1.10–6.61), a lymphocyte count < 1000 cells/µL (OR 2.86; 95 % CI 1.12–7.21) and absence of pneumococcal vaccination (OR 3.50; 95 % CI 1.41–8.70).These results may help to inform clinical decision when considering a treatment by rituximab in immunosuppressed AID patients with hypogammaglobulinemia.